Get the Stockscreener App
53.37
4.13%
-2.30
After Hours:
53.37
Disc Medicine Inc stock is traded at $53.37, with a volume of 660.42K.
It is down -4.13% in the last 24 hours and down -2.45% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$55.67
Open:
$55.3
24h Volume:
660.42K
Relative Volume:
2.02
Market Cap:
$1.84B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-14.54
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-1.77%
1M Performance:
-2.45%
6M Performance:
+7.73%
1Y Performance:
-18.26%
1-Day Range:
$52.70
$56.00
1-Week Range:
$52.70
$57.19
52-Week Range:
$25.60
$68.86
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
53.37 | 1.84B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine’s (IRON) Overweight Rating Reiterated at Morgan Stanley - Defense World
Certain Common Stock of Disc Medicine, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2025. - Marketscreener.com
FY2025 EPS Forecast for Disc Medicine Increased by Analyst - Defense World
New York State Common Retirement Fund Cuts Stake in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Rhumbline Advisers Purchases 1,553 Shares of Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine (NASDAQ:IRON) Price Target Raised to $75.00 at Scotiabank - Defense World
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know - Yahoo Finance
Disc Medicine price target raised to $75 from $73 at Scotiabank - TipRanks
Leerink Partnrs Comments on Disc Medicine Q1 Earnings - Defense World
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus.com
Disc Medicine (NASDAQ:IRON) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Promising Prospects for Disc Medicine: Buy Rating Backed by Bitopertin’s Potential and Strong Financial Health - TipRanks
(IRON) Proactive Strategies - Stock Traders Daily
Disc Medicine’s 2024 Financial Results and Clinical Progress - TipRanks
Disc Medicine's Annual Loss Widens in 2024 -February 27, 2025 at 09:33 am EST - Marketscreener.com
TD Cowen Initiates Coverage on Disc Medicine With Buy Rating -February 27, 2025 at 08:31 am EST - Marketscreener.com
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. Reports Financial Results and Key Clinical Developments, Targeting NDA Submission for Bitopertin in EPP by H2 2025 - Nasdaq
TD Cowen starts Disc Medicine stock with Buy rating By Investing.com - Investing.com UK
Disc Medicine initiated with a Buy at TD Cowen - TipRanks
How Disc Medicine's $490M War Chest Is Fueling Its Path to First FDA Approval - StockTitan
Disc Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Disc Medicine, Inc. (NASDAQ:IRON) Insider Pamela Stephenson Sells 3,137 Shares - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Disc medicine officer sells shares worth $171,217 By Investing.com - Investing.com UK
Disc Medicine’s chief legal officer Rahul Khara sells $63,367 in stock - Investing.com Nigeria
Disc Medicine's chief legal officer Rahul Khara sells $63,367 in stock - Investing.com Australia
Disc medicine COO Yu sells $87,873 in stock By Investing.com - Investing.com South Africa
Disc Medicine CEO John Quisel sells $304,228 in stock By Investing.com - Investing.com Nigeria
Disc medicine officer sells shares worth $171,217 - Investing.com India
Disc medicine COO Yu sells $87,873 in stock - Investing.com
Disc Medicine's chief medical officer sells shares worth $89,402 - Investing.com
Disc Medicine CEO John Quisel sells $304,228 in stock - Investing.com
Disc Medicine Executives Sell Shares to Cover Tax Obligations - TradingView
Disc Medicine CEO Sells Shares to Cover Tax Obligations - TradingView
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Increases By 6.4% - Defense World
Disc Medicine's SWOT analysis: rare blood disorder stock poised for growth - Investing.com
How To Trade (IRON) - Stock Traders Daily
Disc Medicine announces pricing of $225.5M upsized public offering - MSN
Bleakley Financial Group LLC Invests $486,000 in Disc Medicine, Inc. (NASDAQ:IRON) - MarketBeat
FY2025 EPS Estimates for Disc Medicine Increased by Analyst - MarketBeat
Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Disc Medicine FY2025 EPS Forecast Lifted by Leerink Partnrs - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Insider Rahul Khara Sells 7,500 Shares - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):